Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06104488CT.gov A Study of Avutometinib for People With Solid Tumor Cancers | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Optic Pathway Glioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Avutometinib (this asset) | Memorial Sloan Kettering Cancer Center | P1 | CC · 43 |
| Irinotecan | National Cancer Institute (NCI) | P2 | BB |
| Cilengitide | National Cancer Institute (NCI) | P2 | B |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | B |
| Oxaliplatin | National Cancer Institute (NCI) | P2 | CCC |
| Romidepsin | City of Hope Medical Center | P1 | CCC |
| Nivestim | City of Hope Medical Center | P1 | CCC |
| Dexasone | National Cancer Institute (NCI) | P1 | CCC |
| Vorinostat | National Cancer Institute (NCI) | P1 | CCC |
+12 more in the Optic Pathway Glioma cohort
Other indications for Avutometinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Serous Adenocarcinoma | — | P3 | BB · 68 |
| Non-Small Cell Lung Carcinoma | — | P2 | B · 62 |
| Malignant Pancreatic Neoplasm | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- IrinotecanNational Cancer Institute (NCI)BB
- CilengitideNational Cancer Institute (NCI)B
- 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)B
- OxaliplatinNational Cancer Institute (NCI)CCC
- RomidepsinCity of Hope Medical CenterCCC
Citation
Floatz Terminal. Avutometinib in Optic Pathway Glioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/avutometinib-optic-pathway-glioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →